pharmaceutical investing TREMFYA® demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
pharmaceutical investing New TREMFYA® study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
pharmaceutical investing New Johnson & Johnson ICOTYDE® long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
pharmaceutical investing Johnson & Johnson announces new ICOTYDE® data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
pharmaceutical investing New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause
pharmaceutical investing Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® in generalized myasthenia gravis
pharmaceutical investing Johnson & Johnson announces TREMFYA® is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis study
pharmaceutical investing Single infusion of CARVYKTI® delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
pharmaceutical investing RYBREVANT FASPRO plus LAZCLUZE® with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
pharmaceutical investing Johnson & Johnson's RYBREVANT® plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
pharmaceutical investing Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
pharmaceutical investing Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
SAGA Metals Reports Final Titanium, Vanadium and Iron Assays from MRE Drilling--Maiden Mineral Resource Estimate Imminent
